Broadcasting from ESC 2024 - ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI
For patients with a history of myocardial infarction, continuing treatment with beta-blockers could be an unnecessary practice, according to the results of the ABYSS trial.
Coming less than a year after REDUCE-AMI thrust the issue into the spotlight, the ABYSS trial, which was presented at the European Society of Cardiology (ESC) Congress 2024, provides the community with further evidence surrounding use of beta-blocker use in patients with recent myocardial infarction and preserved ejection fraction, but investigators caution further research is needed to solidify these findings.
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
Source: MDMag
